Bio-Gene is an agtech development company enabling the next generation of insecticides to address insecticide resistance.
Studies showed that Flavocide™ EW (oil in water emulsion), exhibited activity against mosquito larvae in contact assays, where it outperformed several commercial products in speed of kill.
The studies were led by Professor Catherine Hill and her team at Purdue University, Indiana, U.S.
Potential for Flavocide as an alternative mosquito management molecule
While Bio-Gene will need to undertake more extensive dose range finding studies, the observed rapid activity was unexpected.
Importantly, it could provide a significant point of difference and create a number of opportunities for ongoing development of Flavocide either alone or in combination with other insecticides.
With limited options for alternative mosquito management molecules, there may be potential for Flavocide as part of an integrated resistance management strategy.
This could be vital for the long-term control of mosquitoes globally.
Mosquito bites result in more than one million deaths per year
According to the World Health Organisation, mosquito bites result in the deaths of more than one million humans per year, acting as vectors for many serious diseases.
Melbourne-based Bio-Gene listed on the ASX in November 2017 after raising $7.1 million in its initial public offering.
The company has signed an agreement with Virbac SA (EPA:VIRP), a France-based multinational animal health company, as part of the commercialisation process for its insecticide products.